Neulasta (pegfilgrastim), a new long-acting form of Neupogen (filgrastim)
April 2002
Amgen will soon launch Neulasta (pegfilgrastim), a new long-acting form of Neupogen (filgrastim).
It's a new option for preventing infection in chemo patients. Neulasta and Neupogen stimulate the production of white blood cells.
Neulasta is made by attaching polyethylene glycol (PEG) to filgrastim. The "pegylated" version is cleared more slowly so it can be given less often.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote